# A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

> **NCT05587309** · PHASE3 · COMPLETED · sponsor: **Braintree Laboratories** · enrollment: 1250 (actual)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** BLI5100
- **DRUG:** PPI Control

## Key facts

- **NCT ID:** NCT05587309
- **Lead sponsor:** Braintree Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-30
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-06-16
- **Target enrollment:** 1250 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05587309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05587309, "A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05587309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*